Published in Blood on July 06, 2007
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A (2013) 2.47
Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol (2010) 2.44
FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo. Blood (2008) 2.31
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood (2008) 2.13
Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst (2012) 2.09
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood (2011) 2.02
Regulatory T cells and treatment of cancer. Curr Opin Immunol (2008) 2.01
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest (2011) 1.82
Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells. J Immunol (2008) 1.58
Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov (2013) 1.50
TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol (2008) 1.43
Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood (2009) 1.35
Pregnancy induces a fetal antigen-specific maternal T regulatory cell response that contributes to tolerance. Proc Natl Acad Sci U S A (2010) 1.26
Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection. Blood (2008) 1.25
B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol (2010) 1.10
Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol (2010) 1.10
Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol (2008) 1.06
Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol (2010) 1.02
Delicate balance among three types of T cells in concurrent regulation of tumor immunity. Cancer Res (2013) 1.02
New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol (2013) 1.01
Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. Blood (2011) 1.01
Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res (2012) 1.01
An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS One (2014) 0.97
Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates. J Immunol (2012) 0.95
The role of regulatory T cells in cancer. Immune Netw (2009) 0.93
Development of a diphtheria toxin-based recombinant porcine IL-2 fusion toxin for depleting porcine CD25+ cells. J Immunol Methods (2013) 0.92
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. BMC Cancer (2011) 0.91
Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res (2016) 0.89
New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) (2011) 0.89
Cancer vaccines: Looking to the future. Oncoimmunology (2013) 0.88
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol (2011) 0.88
Combating immunosuppression in glioma. Future Oncol (2008) 0.87
Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. J Immunother (2009) 0.87
Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol (2013) 0.86
Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res (2014) 0.85
Advancements in immune tolerance. Adv Drug Deliv Rev (2007) 0.82
The role of regulatory T cells in cancer immunology. Immunotargets Ther (2015) 0.82
Inhibition of TGF-β1 signaling promotes central memory T cell differentiation. J Immunol (2013) 0.81
Up-regulation of Th17 cells may underlie inhibition of Treg development caused by immunization with activated syngeneic T cells. PLoS One (2011) 0.81
Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy. Mol Cancer (2014) 0.80
Distinct effects of saracatinib on memory CD8+ T cell differentiation. J Immunol (2012) 0.80
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). Ther Adv Hematol (2016) 0.79
A novel oxygen carrier "YQ23" suppresses the liver tumor metastasis by decreasing circulating endothelial progenitor cells and regulatory T cells. BMC Cancer (2014) 0.79
Anti-GITR therapy promotes immunity against malignant glioma in a murine model. Cancer Immunol Immunother (2016) 0.78
Cancer vaccines: current directions and perspectives in prostate cancer. Curr Opin Mol Ther (2009) 0.78
Therapeutic enhancement of protective immunity during experimental leishmaniasis. PLoS Negl Trop Dis (2011) 0.78
Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. Am J Cancer Res (2015) 0.78
Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine. Mol Med Rep (2015) 0.78
Immunotherapy: a useful strategy to help combat multidrug resistance. Drug Resist Updat (2012) 0.78
Recombinant adenovirus IL-24-Bax promotes apoptosis of hepatocellular carcinoma cells in vitro and in vivo. Cancer Gene Ther (2010) 0.77
Pattern response of dendritic cells in the tumor microenvironment and breast cancer. World J Clin Oncol (2014) 0.76
Targeting Treg cells in situ: emerging expansion strategies for (CD4(+)CD25(+)) regulatory T cells. Biol Blood Marrow Transplant (2009) 0.75
Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells. Oncoimmunology (2014) 0.75
Current perspectives in prostate cancer vaccines. Anticancer Agents Med Chem (2009) 0.75
Forkhead box P3-positive regulatory T cells in immune surveillance and cancer. Br J Cancer (2007) 0.75
Biphasic rapamycin effects in lymphoma and carcinoma treatment. Cancer Res (2016) 0.75
Construction and Production of Foxp3-Fc (IgG) DNA Vaccine/Fusion Protein. Avicenna J Med Biotechnol (2016) 0.75
Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. Breast Care (Basel) (2016) 0.75
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products. Drugs (2015) 0.75
Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma. Oncotarget (2016) 0.75
DAB389IL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice. Immunopharmacol Immunotoxicol (2017) 0.75
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol (2007) 6.92
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res (2001) 5.48
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res (1999) 5.41
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02
Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol (2005) 3.65
Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res (2003) 3.44
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol (2004) 2.84
Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res (2003) 2.45
CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer (2003) 2.37
A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res (1999) 2.33
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res (2004) 2.28
Control of immune homeostasis by naturally arising regulatory CD4+ T cells. Curr Opin Immunol (2003) 2.04
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother (2005) 2.01
Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol (2005) 1.96
The bone marrow: a nest for migratory memory T cells. Trends Immunol (2005) 1.88
Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer (2007) 1.85
Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res (2002) 1.77
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res (2006) 1.62
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst (1992) 1.59
Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J Virol (1996) 1.58
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol (2006) 1.53
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol (2006) 1.52
Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res (2001) 1.51
Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res (1998) 1.40
Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res (2001) 1.35
The peripheral generation of CD4+ CD25+ regulatory T cells. Immunology (2003) 1.25
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res (2005) 1.20
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol (2006) 1.12
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol (2007) 1.10
T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med (2003) 1.08
Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res (2002) 1.03
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood (1998) 1.02
Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res (1996) 0.90
Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. Clin Cancer Res (2004) 0.88
Denileukin diftitox: a concise clinical review. Expert Rev Anticancer Ther (2005) 0.85
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res (2004) 2.91
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res (2004) 2.54
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 2.44
CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res (2005) 2.38
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res (2004) 2.28
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J Immunol (2003) 2.18
CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res (2010) 2.13
The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest (2010) 1.98
Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol (2005) 1.96
Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res (2008) 1.83
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest (2011) 1.82
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res (2002) 1.77
IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res (2011) 1.73
The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res (2007) 1.65
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res (2008) 1.59
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59
Multiple costimulatory modalities enhance CTL avidity. J Immunol (2005) 1.58
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) (2011) 1.50
Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res (2005) 1.49
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res (2010) 1.45
Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res (2003) 1.44
After the storm--health care infrastructure in post-Katrina New Orleans. N Engl J Med (2006) 1.42
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res (2012) 1.38
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine (2006) 1.38
Costimulatory molecules as adjuvants for immunotherapy. Front Biosci (2006) 1.37
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res (2006) 1.36
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer (2013) 1.35
Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol (2003) 1.34
Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res (2006) 1.31
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res (2010) 1.30
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood (2012) 1.30
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res (2005) 1.28
Strategies for cancer vaccine development. J Biomed Biotechnol (2010) 1.26
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol (2002) 1.24
NK cells help to induce CD8(+)-T-cell immunity against Toxoplasma gondii in the absence of CD4(+) T cells. Infect Immun (2005) 1.23
Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci (Landmark Ed) (2009) 1.23
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol (2008) 1.22
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res (2005) 1.20
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother (2010) 1.17
IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8+ T cell responses and increases the ratio of effector/memory CD8+ T cells to regulatory T cells. J Immunol (2008) 1.16
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res (2013) 1.16
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res (2004) 1.15
Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm (2004) 1.15
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res (2008) 1.14
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res (2005) 1.14
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res (2002) 1.14
Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res (2011) 1.14
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother (2014) 1.13
Vaccines with enhanced costimulation maintain high avidity memory CTL. J Immunol (2005) 1.12
Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res (2009) 1.12
B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol (2010) 1.10
Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res (2002) 1.10
Regulatory T-cell development: is Foxp3 the decider? Nat Med (2007) 1.10
Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas. Semin Oncol (2012) 1.10
Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res (2008) 1.09
Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol (2012) 1.09
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol (2007) 1.07
ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob Agents Chemother (2009) 1.07
Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res (2003) 1.05
Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction. J Immunol (2002) 1.05
Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res (2002) 1.04
Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol (2004) 1.04
Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine (2007) 1.04
Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res (2002) 1.03
Vaccines against human carcinomas: strategies to improve antitumor immune responses. J Biomed Biotechnol (2010) 1.02
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine (2006) 1.02
p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol (2006) 1.02
A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother (2012) 1.02
Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells. J Immunol (2010) 1.01
Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res (2012) 1.01
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. J Immunol (2013) 1.01